請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77912完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 孔令傑 | |
| dc.contributor.author | Yu-Chien Tsao | en |
| dc.contributor.author | 曹宇茜 | zh_TW |
| dc.date.accessioned | 2021-07-11T14:37:16Z | - |
| dc.date.available | 2020-09-04 | |
| dc.date.copyright | 2017-09-04 | |
| dc.date.issued | 2017 | |
| dc.date.submitted | 2017-08-11 | |
| dc.identifier.citation | 1. Caplan, L.R., Intracranial branch atheromatous disease: a neglected, understudied, and underused concept. Neurology, 1989. 39(9): p. 1246-50.
2. Krishnamurthi, R.V., et al., Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health, 2013. 1(5): p. e259-81. 3. Caplan, L.R., Caplan's stroke; a clinical approach, 4th ed. 2009. 4. Adams, H.P., Jr., et al., Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke, 1993. 24(1): p. 35-41. 5. Hsieh, F.I., et al., Get With the Guidelines-Stroke performance indicators: surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-Stroke in Taiwan. Circulation, 2010. 122(11): p. 1116-23. 6. Lee, T.H., et al., Etiologic study of young ischemic stroke in Taiwan. Stroke, 2002. 33(8): p. 1950-5. 7. Huang, Z.S., T.L. Chiang, and T.K. Lee, Stroke prevalence in Taiwan. Findings from the 1994 National Health Interview Survey. Stroke, 1997. 28(8): p. 1579-84. 8. Lin, H.C., et al., Urbanization and stroke prevalence in Taiwan: analysis of a nationwide survey. J Urban Health, 2007. 84(4): p. 604-14. 9. Hsieh, F.I. and H.Y. Chiou, Stroke: morbidity, risk factors, and care in taiwan. J Stroke, 2014. 16(2): p. 59-64. 10. Tong, X., et al., Trends in hospitalizations and cost associated with stroke by age, United States 2003-2012. Int J Stroke, 2016. 11. Kleindorfer, D., et al., National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke, 2008. 39(3): p. 924-8. 12. Wardlaw, J.M., et al., Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev, 2014. 7: p. Cd000213. 13. Adeoye, O., et al., Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke, 2011. 42(7): p. 1952-5. 14. Hsieh, C.Y., et al., National survey of thrombolytic therapy for acute ischemic stroke in Taiwan 2003-2010. J Stroke Cerebrovasc Dis, 2013. 22(8): p. e620-7. 15. Wang, Y., et al., Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke, 2011. 42(6): p. 1658-64. 16. Lee, B.C. and J.K. Roh, International experience in stroke registries: Korean Stroke Registry. Am J Prev Med, 2006. 31(6 Suppl 2): p. S243-5. 17. Sato, S., et al., Impact of the approval of intravenous recombinant tissue plasminogen activator therapy on the processes of acute stroke management in Japan: the Stroke Unit Multicenter Observational (SUMO) Study. Stroke, 2009. 40(1): p. 30-4. 18. Evenson, K.R., et al., A comprehensive review of prehospital and in-hospital delay times in acute stroke care. Int J Stroke, 2009. 4(3): p. 187-99. 19. Sung, S.F. and M.C. Tseng, Code stroke: a mismatch between number of activation and number of thrombolysis. J Formos Med Assoc, 2014. 113(7): p. 442-6. 20. Hsieh, C.Y., et al., Efforts to reduce the door-to-needle time of thrombolysis in acute ischemic stroke: video-assisted therapeutic risk communication. J Formos Med Assoc, 2014. 113(12): p. 929-33. 21. Sun, M.C. and P.J. Hsiao, Time cost of a nonclosing intravenous thrombolysis service for acute ischemic stroke. J Formos Med Assoc, 2015. 114(10): p. 910-5. 22. Shook, T.L., et al., Comparison of percutaneous transluminal coronary angioplasty outcome and hospital costs for low-volume and high-volume operators. Am J Cardiol, 1996. 77(5): p. 331-6. 23. Slattery, W.H., et al., Acoustic neuroma surgical cost and outcome by hospital volume in California. Otolaryngol Head Neck Surg, 2004. 130(6): p. 726-35. 24. Martineau, P., et al., Primary hip arthroplasty costs are greater in low-volume than in high-volume Canadian hospitals. Clin Orthop Relat Res, 2005(437): p. 152-6. 25. Hall, R.E., et al., Does the Volume of Ischemic Stroke Admissions Relate to Clinical Outcomes in the Ontario Stroke System? Circ Cardiovasc Qual Outcomes, 2015. 8(6 Suppl 3): p. S141-7. 26. Lin, H.C., et al., Association between physician volume and hospitalization costs for patients with stroke in Taiwan: a nationwide population-based study. Stroke, 2007. 38(5): p. 1565-9. 27. Luft, H.S., S.S. Hunt, and S.C. Maerki, The volume-outcome relationship: practice-makes-perfect or selective-referral patterns? Health Serv Res, 1987. 22(2): p. 157-82. 28. Jin, H., et al., Factors associated with prehospital delays in the presentation of acute stroke in urban China. Stroke, 2012. 43(2): p. 362-70. 29. Bouckaert, M., R. Lemmens, and V. Thijs, Reducing prehospital delay in acute stroke. Nat Rev Neurol, 2009. 5(9): p. 477-83. 30. Chen, C.H., et al., Pre-hospital and in-hospital delays after onset of acute ischemic stroke: a hospital-based study in southern Taiwan. Kaohsiung J Med Sci, 2007. 23(11): p. 552-9. 31. Chen, C.H., et al., Stroke code improves intravenous thrombolysis administration in acute ischemic stroke. PLoS One, 2014. 9(8): p. e104862. 32. Database., N.H.I.R., http://english.nhri.org.tw/NHRI_WEB/nhriw001Action.do. 33. Cheng, C.L., et al., Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf, 2011. 20(3): p. 236-42. 34. Sung, S.F., et al., Developing a stroke severity index based on administrative data was feasible using data mining techniques. J Clin Epidemiol, 2015. 68(11): p. 1292-300. 35. Hsieh, C.Y., et al., 'Weekend effect' on stroke mortality revisited: Application of a claims-based stroke severity index in a population-based cohort study. Medicine (Baltimore), 2016. 95(25): p. e4046. 36. Tung, Y.C., G.M. Chang, and Y.H. Chen, Associations of physician volume and weekend admissions with ischemic stroke outcome in Taiwan: a nationwide population-based study. Med Care, 2009. 47(9): p. 1018-25. 37. Wu, C.Y., H.J. Lai, and R.C. Chen, Patient characteristics predict occurrence and outcome of complaints against physicians: a study from a medical center in central Taiwan. J Formos Med Assoc, 2009. 108(2): p. 126-34. 38. Paul, C.L., et al., How can we improve stroke thrombolysis rates? A review of health system factors and approaches associated with thrombolysis administration rates in acute stroke care. Implement Sci, 2016. 11: p. 51. 39. Busis, N.A., et al., Burnout, career satisfaction, and well-being among US neurologists in 2016. Neurology, 2017. 88(8): p. 797-808. 40. Schumacher, H.C., et al., Use of thrombolysis in acute ischemic stroke: analysis of the Nationwide Inpatient Sample 1999 to 2004. Ann Emerg Med, 2007. 50(2): p. 99-107. 41. Allison, J.J., et al., Relationship of hospital teaching status with quality of care and mortality for Medicare patients with acute MI. Jama, 2000. 284(10): p. 1256-62. 42. Goldstein, L.B., et al., Charlson Index comorbidity adjustment for ischemic stroke outcome studies. Stroke, 2004. 35(8): p. 1941-5. 43. Hoh, B.L., et al., Effect of weekend compared with weekday stroke admission on thrombolytic use, in-hospital mortality, discharge disposition, hospital charges, and length of stay in the Nationwide Inpatient Sample Database, 2002 to 2007. Stroke, 2010. 41(10): p. 2323-8. 44. Huff, J.S., Stroke mimics and chameleons. Emerg Med Clin North Am, 2002. 20(3): p. 583-95. 45. Chen, W.H., et al., The medicolegal issue of tissue plasminogen activator in ischemic stroke: a review of judiciary decrees in Taiwan. Acta Neurol Taiwan, 2011. 20(3): p. 163-71. 46. Powers, W.J., et al., 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2015. 46(10): p. 3020-35. 47. Audebert, H.J. and L. Schwamm, Telestroke: scientific results. Cerebrovasc Dis, 2009. 27 Suppl 4: p. 15-20. 48. Yperzeele, L., et al., Prehospital stroke care: limitations of current interventions and focus on new developments. Cerebrovasc Dis, 2014. 38(1): p. 1-9. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77912 | - |
| dc.description.abstract | 靜脈注射rt-PA是唯一經美國食管局批准的急性腦梗塞治療藥物。台灣的rt-PA施打率約為0.60％, 相比之下較低於其他亞洲已開發國家。我們的研究目標，是藉由評估醫院特點、人力資源和rt-PA施打率之間的關係，來釐清rt-PA施打率較低的原因。
由於先前的研究已知台灣各地區的施打率不盡相同，故在此研究中也有將地區設作控制變數。在控制地區這個因素之後，我們發現急診醫師的數量、急診醫生的年齡、中風的嚴重程度和中風的季節與rt-PA的施打率有相關。基於以上觀察，我們認為急診醫師可能是急性腦中風治療計劃的關鍵決策者。希望後續有進一步的研究及相關的政策調整，以解決急診醫師人力資源短缺及急性腦中風低治療率的問題。 | zh_TW |
| dc.description.abstract | Intravenous (IV) recombinant tissue-type plasminogen activator (rt-PA) is the only Food and Drug Administration-approved therapy for acute ischemic stroke (AIS). The rt-PA utilization rate is relatively low in Taiwan. Therefore, we aim to evaluate the barriers of AIS treatment by evaluating the relationships among hospital’s characteristics, human resources, and the rt-PA administration rate.
Previous study shows that the rt-PA administration rates are different in different region in Taiwan. After controlling the regional factors, we find that the number of the emergency physicians, the age of emergency physicians, the severity of stroke, and the season are related with the rt-PA administration. Hence, we suggest that the emergency physician might be the key decision maker to initiate the code stroke and efficient thrombolysis therapy. Further nationwide survey to clarify the phenomenon, and the policy to solve the human resources shortage should be applied in the future. By improving the AIS treatment, we hope to decrease the economic burden of stroke in healthcare system. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-11T14:37:16Z (GMT). No. of bitstreams: 1 ntu-106-R03749010-1.pdf: 724692 bytes, checksum: 4b877abcf38aab9a7aeb5382244a107b (MD5) Previous issue date: 2017 | en |
| dc.description.tableofcontents | 謝辭 III
中文摘要 IV ABSTRACT V CHAPTER 1 INTRODUCTION 2 1.1 Research background 2 1.2 Research motivation 4 1.3 Research objectives 6 1.4 Research plan 7 CHAPTER 2 LITERATURE REVIEW 8 2.1 Management of AIS and the causes of delayed treatment: pre-hospital delay and in-hospital delay 8 2.2 The NHIRD validity and AIS studies in volume-outcome phenomenon 10 2.3 The current AIS management in Taiwan 13 2.4 Optimal strategy for resources allocation 14 CHAPTER 3 PROBLEM DESCRIPTION 15 3.1 Problem description and hypotheses 15 3.2The NHIRD and variables of interest 17 3.2 Definition of AIS Admission and Thrombolytic Therapy 21 CHAPTER 4 RESULT 26 4.1 Descriptive analysis of the result 26 4.2 Regression analysis 36 CHAPTER 5 CONCLUSIONS 39 BIBLIOGRAPHY 43 APPENDIX A 47 | |
| dc.language.iso | en | |
| dc.subject | 人力配置 | zh_TW |
| dc.subject | 中風 | zh_TW |
| dc.subject | 血栓溶解劑 | zh_TW |
| dc.subject | human resource | en |
| dc.subject | rt-PA | en |
| dc.subject | stroke | en |
| dc.title | rt-PA施打率以及醫院人力配置的關聯 | zh_TW |
| dc.title | rt-PA administration rate and the human resource allocation in hospitals | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 105-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 林真如,莊皓鈞,裘家寧 | |
| dc.subject.keyword | 血栓溶解劑,中風,人力配置, | zh_TW |
| dc.subject.keyword | rt-PA,stroke,human resource, | en |
| dc.relation.page | 61 | |
| dc.identifier.doi | 10.6342/NTU201702921 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2017-08-11 | |
| dc.contributor.author-college | 管理學院 | zh_TW |
| dc.contributor.author-dept | 企業管理碩士專班 | zh_TW |
| 顯示於系所單位： | 管理學院企業管理專班(Global MBA) | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-106-R03749010-1.pdf 未授權公開取用 | 707.71 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。